Xilis

The MOS technology creates microscale tumors that maintain the structure, genetic alterations, gene expression, immune microenvironment, and histopathology of individual patients' tumors. This allows for rapid diagnostics and personalized therapy prioritization by predicting patient response. It also provides scalable patient-derived models for high-throughput and immuno-oncology drug discovery.

The Precision Oncology Platform aids clinicians in making timely treatment decisions by predicting patient treatment response and suggesting optimal therapeutic options. The Xilis Response ScoreTM, a part of this platform, can guide prioritized treatment decisions for oncologists and ensure patients receive the right drug at the right time.

Xilis' business model is centered around providing an end-to-end patient-centric solution that transforms cancer drug development. This includes cost-effective, high-throughput drug candidate screening, pre-clinical assessment of immuno-oncology drugs, personalized assays to determine patient eligibility for clinical trials, and companion diagnostics to guide patients to newly developed treatments.

The company's primary clients are oncologists and other healthcare professionals involved in cancer treatment, as well as pharmaceutical companies engaged in drug discovery and development.